tailieunhanh - Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptorpositive advanced breast cancer

Entinostat is an oral inhibitor of class I histone deacetylases intended for endocrine therapy-resistant patients with hormone receptor-positive (HR+) advanced or metastatic breast cancer (BC). We examined the safety, efficacy, and pharmacokinetics of entinostat monotherapy and combined entinostat/exemestane in Japanese patients. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN